General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting, 39882-39883 [2011-16952]
Download as PDF
39882
Federal Register / Vol. 76, No. 130 / Thursday, July 7, 2011 / Notices
approximately 1,400, audit reports to be
submitted.
Because FDA expects that the vast
majority of manufacturers who will
participate in the Voluntary Audit
Report Submission Program will be
manufacturers certified by Health
Canada under ISO 13485:2003, FDA
expects the number of reports to be
submitted from manufacturers certified
by regulatory systems established by
other founding GHTF members to be
minimal. For purposes of calculating the
reporting burden, FDA estimates that
approximately 10 percent of total audit
reports submitted under this program
will be from these other manufacturers.
Because 90 percent of the audit reports
are expected to be submitted by
manufacturers certified by Health
Canada (approximately 1,400 audit
reports as calculated previously in this
document), the total number of audit
reports FDA expects to receive in a year
is 1,556, or approximately 1,600 audit
reports.
FDA estimates from past experience
with the Electronic Submission Gateway
system, WebTrader, that the first year to
set up the account and to receive the
verification certificate takes
approximately 40 hours. This burden
may be minimized if the Respondent
already has an established account in
WebTrader for other electronic
submissions to FDA but FDA is
assuming that all respondents to this
new pilot program will be setting up a
WebTrader account for the first time in
the first year. For subsequent years, the
estimate burden hours are estimated at
1 hour to renew the yearly required
verification certification.
FDA further estimates that the
gathering, scanning, and submission of
the audit reports, certificates, and
related correspondence would take
approximately 2 hours utilizing the
eSubmitter system.
Therefore, the first year will include
40 hours for the WebTrader system plus
2 hours for the eSubmitter submission
process, resulting in 42 hours per
response for the first year. For both the
second and third years, it is estimated
that only 1 hour will be necessary for
the WebTrader system plus the 2 hours
for the eSubmitter submission process,
resulting in 3 hours per response each
year thereafter.
The draft guidance also refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by OMB under the
PRA. The collections of information in
21 CFR part 820 have been approved
under OMB control number 0910–0073
and the collections of information for
the Inspection by Accredited Persons
Program have been approved under
OMB control number 0910–0569.
In the Federal Register of May 20,
2010 (75 FR 28257), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. FDA received one
comment which was related to the PRA
reporting burden.
The comment stated that the reporting
burden hours may be too low for the
first submission and may take less time
for subsequent submissions. In addition,
this comment stated that the number of
reports anticipated to be submitted may
be a high estimate by a factor of 10. FDA
appreciates the consideration of burden
hours by the comment. The comment,
however, did not provide any data to
assist FDA to adjust the burden hours
for the submission. Absent baseline
information at this time, FDA will
review the submissions during the pilot
period and modify the burden to
respondents accordingly.
FDA estimates the burden of this
collection of information as follows:
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN
No. of
responses per
respondent
per year
No. of
respondents
Average
burden per
response
(in hours)
Total annual
responses
Total hours
Capital and
operating and
maintenance
costs
First year ................................................
Second year (recurring) .........................
Third year (recurring) .............................
1,600
1,600
1,600
1
1
1
1,600
1,600
1,600
142
3
3
67,200
4,800
4,800
2,016,000
48,000
48,000
Totals ..............................................
........................
........................
........................
........................
76,800
2,112,000
1Respondent
may already have a valid WebTrader account established for other FDA electronic submissions.
There are capital, start-up, operating,
or maintenance cost associated with this
information collection. The costs are
$30 per year to establish and maintain
the Electronic Submission Gateway
verification certificate.
Dated: July 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0478]
General and Plastic Surgery Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting
[FR Doc. 2011–17051 Filed 7–6–11; 8:45 am]
AGENCY:
BILLING CODE 4160–01–P
Food and Drug Administration,
sroberts on DSK5SPTVN1PROD with NOTICES
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
VerDate Mar<15>2010
16:26 Jul 06, 2011
Jkt 223001
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Name of Committee: General and
Plastic Surgery Devices Panel of the
Medical Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on August 30 and 31, 2011, from
8 a.m. to 6 p.m.
Addresses: FDA is opening a docket
for public comment on this document.
The docket will open for public
comment on July 7, 2011. The docket
will close on August 26, 2011.
Interested persons may submit
electronic or written comments
regarding this document. Submit
electronic comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
E:\FR\FM\07JYN1.SGM
07JYN1
sroberts on DSK5SPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 130 / Thursday, July 7, 2011 / Notices
Management, Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit a
single copy of electronic comments or
two paper copies of any mailed
comments, except that individuals may
submit one paper copy. Comments are
to be identified with the docket number
found in brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Location: Hilton Washington DC
North/Gaithersburg, Ballroom, 620 Perry
Pkwy., Gaithersburg, MD.
Contact Person: Margaret McCabeJanicki, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1535, Silver Spring,
MD 20993–0002, 301–796–7029, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.
Agenda: On August 30 and 31, 2011,
the committee will discuss and make
recommendations on postmarketing
issues related to silicone gel-filled breast
implants. This meeting is regarding the
discussion of different innovative
methodological approaches to the
conduct of postmarket studies regarding
silicone gel breast implants.
Additionally, the panel will discuss key
long-term safety issues associated with
silicone gel breast implants in the realworld setting.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
VerDate Mar<15>2010
16:26 Jul 06, 2011
Jkt 223001
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 24, 2011.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 3 p.m. on August 30, 2011, and
between approximately 8 a.m. and 10
a.m. on August 31, 2011. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 15, 2011. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 17, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams, Conference Management
Staff, 301–796–5966, at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 23, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–16952 Filed 7–6–11; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
39883
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Design of Clinical Trials for Systemic
Antibacterial Drugs for the Treatment
of Acute Otitis Media; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration (FDA) is announcing a
public workshop regarding the design of
Clinical Trials for Systemic
Antibacterial Agents for the Treatment
of Acute Otitis Media. This public
workshop is intended to provide
information for and gain perspective
from health care providers, patients and
patient advocacy organizations,
academia, and industry on various
aspects of the design of clinical trials.
The input from this public workshop
will help in developing topics for
further discussion.
Dates and Times: The public
workshop will be held on September 7,
2011 from 8:30 a.m. to 5 p.m.
Location: The public workshop will
be held at the Crowne Plaza, 8777
Georgia Ave., Silver Spring, MD 20910,
301–589–0800. Seating is limited and
available only on a first-come, firstserved basis.
Contact Persons: Christine Moser or
Ramou Mauer, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 6193,
Silver Spring, MD 20993–0002, 301–
796–1300.
Registration: Registration is free for
the public workshop. Interested parties
are encouraged to register early. Seating
will be available on a first-come, firstserved basis. To register electronically,
e-mail registration information
(including name, title, firm name,
address, telephone, and fax number) to
Otitisworkshop@fda.hhs.gov. Persons
without access to the Internet may call
301–796–1300 to register. Persons
needing a sign language interpreter or
other special accommodations should
notify Christine Moser or Lori Benner
(see Contact Persons) at least 7 days in
advance.
SUPPLEMENTARY INFORMATION: FDA is
announcing a public workshop
regarding scientific considerations in
the design of clinical trials of
antibacterial agents for the treatment of
acute otitis media (middle ear
infection). Discussions will focus on
SUMMARY:
E:\FR\FM\07JYN1.SGM
07JYN1
Agencies
[Federal Register Volume 76, Number 130 (Thursday, July 7, 2011)]
[Notices]
[Pages 39882-39883]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-16952]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0478]
General and Plastic Surgery Devices Panel of the Medical Devices
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: General and Plastic Surgery Devices Panel of the
Medical Devices Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on August 30 and 31, 2011,
from 8 a.m. to 6 p.m.
Addresses: FDA is opening a docket for public comment on this
document. The docket will open for public comment on July 7, 2011. The
docket will close on August 26, 2011. Interested persons may submit
electronic or written comments regarding this document. Submit
electronic comments to https://www.regulations.gov. Submit written
comments to the Division of Dockets
[[Page 39883]]
Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Submit a single copy of electronic comments or two
paper copies of any mailed comments, except that individuals may submit
one paper copy. Comments are to be identified with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday.
Location: Hilton Washington DC North/Gaithersburg, Ballroom, 620
Perry Pkwy., Gaithersburg, MD.
Contact Person: Margaret McCabe-Janicki, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1535, Silver Spring, MD 20993-0002, 301-796-7029,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), and follow the prompts to the desired
center or product area. Please call the Information Line for up-to-date
information on this meeting. A notice in the Federal Register about
last minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
and call the appropriate advisory committee hot line/phone line to
learn about possible modifications before coming to the meeting.
Agenda: On August 30 and 31, 2011, the committee will discuss and
make recommendations on postmarketing issues related to silicone gel-
filled breast implants. This meeting is regarding the discussion of
different innovative methodological approaches to the conduct of
postmarket studies regarding silicone gel breast implants.
Additionally, the panel will discuss key long-term safety issues
associated with silicone gel breast implants in the real-world setting.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
August 24, 2011. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 3 p.m. on August 30, 2011, and between
approximately 8 a.m. and 10 a.m. on August 31, 2011. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before August 15, 2011. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by August 17, 2011.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact AnnMarie Williams,
Conference Management Staff, 301-796-5966, at least 7 days in advance
of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: June 23, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-16952 Filed 7-6-11; 8:45 am]
BILLING CODE 4160-01-P